The HER2 CISH pharmDx ™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

By Foged Niels T   Brügmann Anja   Jørgensen Jan T  

Expert Review of Molecular Diagnostics, Vol. 13, Iss. 3, 2013-04 ,pp. : 233-242

Informa Healthcare

Access to resources Recommend Favorite

Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts

By Balandin Taras   Edelweiss Evelina   Andronova Natalia   Treshalina Elena   Sapozhnikov Alexander   Deyev Sergey  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 22-32

Springer Publishing Company

Access to resources Recommend Favorite

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

By Coyne C. P.   Ross Matt   Bailey John  

Journal of Drug Targeting, Vol. 17, Iss. 6, 2009-07 ,pp. : 474-489

Informa Healthcare

Access to resources Recommend Favorite

Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

By Bartlett John M.S.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 5, 2005-01 ,pp. : 303-315

Adis International

Access to resources Recommend Favorite

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite